Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology Rigel (Nasdaq: RIGL) announced publication of final Phase 1/2 ARROW data for GAVRETO (pralsetinib) in RET fusion-positive NSCLC in the Journal of Clinical Oncology on March 31, 2026.Key results: overall response rate 70% (n=259), treatment-naive ORR 78%, median OS 44.3 months, median PFS 13.1 months, intracranial ORR 53% (15 patients); safety described as manageable with three treatment-related deaths reported.

#RIGL Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

www.stocktitan.net/news/RIGL/rigel-announce...

Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Rigel (Nasdaq: RIGL) reported Q4 2025 revenue of $69.8M and full-year 2025 revenue of $294.3M, driven by record net product sales of $65.4M in Q4 and $232.0M for the year. Net income was $268.1M in Q4 and $367.0M for 2025, largely reflecting a $245.9M non-cash deferred tax benefit.Commercial growth, advancing R289 Phase 1b enrollment, recent clinical data releases, FDA labeling update for GAVRETO, and 2026 guidance of $275–$290M revenue support the company outlook.

#RIGL Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/RIGL/rigel-provides...

Rigel Provides Business Update and 2026 Outlook RBC-TI was achieved by 33% of evaluable transfusion dependent patients receiving R289 doses≥ 500 mg QD, including 40% in the 500 mg BID dose group Enrollment in the dose expansion phase of the Phase 1 b study is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026 2026...

#RIGL Rigel Provides Business Update and 2026 Outlook

www.stocktitan.net/news/RIGL/rigel-provides...

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition Rigel (Nasdaq: RIGL) presented updated Phase 1b data for R289, an oral prodrug of R835, in relapsed/refractory lower-risk MDS at ASH on December 7, 2025.Key results as of October 28, 2025: 33 patients (median age 75, median 3 prior therapies) were treated; at doses ≥500 mg QD 6/18 (33%) transfusion-dependent patients achieved durable RBC-TI (>8 weeks), with median time to RBC-TI 1.9 months and median duration 22.9 weeks. R289 was generally well tolerated; common Grade 1/2 AEs included diarrhea (30%) and fatigue (27%). One DLT occurred at 750 mg.

#RIGL Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

www.stocktitan.net/news/RIGL/rigel-presents...

Breaking News: ( NASDAQ: #RIGL ) Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology Rigel (NASDAQ: RIGL) published final five-year results from the Phase 2 pivotal cohort of REZLIDHIA (olutasidenib) in relapsed/refractory mIDH1 acute myeloid leukemia in Journal of Hematology & Oncology on Nov 17, 2025. Key five-year findings: CR/CRh 35% (n=147) with median duration 25.3 months, ORR 48% with median duration 15.5 months, and overall median OS 11.5 months. Safety remained consistent with no new signals or new cases of differentiation syndrome reported.Subgroup: patients with 1–2 prior regimens showed higher response rates and longer OS versus ≥3 prior regimens; 12 patients R/R to venetoclax had 33% CR/CRh and median OS 16.2 months.

#RIGL Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

www.stocktitan.net/news/RIGL/rigel-announce...

Trade Alerts, Thursday November 6, 2025 – Crystal Equity Research

Small-cap stocks in new ADX uptrend, Thu Nov 6th - #ATPC #UFPT #SRTS #RIGL #PDSB #FRBA #EOLS #BFST #ACNT #TDC #MITT #FSLY #DBI #BGS - More: crystalequityresearch.com/trade-alerts... - #smallcap

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million Generated $27.9 million of net income in the third quarter of 2025 Completed enrollment in the dose escalation phase and enrolled the first patient in the dose expansion phase of...

#RIGL Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/RIGL/rigel-reports-...

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition Rigel (Nasdaq: RIGL) will present updated clinical data at the 67th ASH Annual Meeting, Dec 6-9, 2025, in Orlando and virtually.An oral presentation (Dec 7) will report updated Phase 1b safety and efficacy for R289 in relapsed/refractory lower‑risk MDS: dose range 250 mg QD to 500 mg BID, 33 patients enrolled (data cutoff Jul 15, 2025), median age 75, 61% high transfusion burden. At ≥500 mg QD evaluable transfusion‑dependent patients, 4/13 (31%) achieved durable RBC‑TI (>8 weeks); median time to RBC‑TI 2.2 months and median duration 24.3 weeks.Four posters (Dec 6–8) report REZLIDHIA (olutasidenib) data in R/R mIDH1 AML, including late responses after stable disease, real‑world post‑venetoclax outcomes, hematologic improvement timing, and outcomes after prior intensive chemotherapy.

#RIGL Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

www.stocktitan.net/news/RIGL/rigel-announce...

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS. SOUTH SAN FRANCISCO, Calif., Oct. 8, 2025/ PRNewswire/-- Rigel Pharmaceuticals, Inc., a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the...

#RIGL Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

www.stocktitan.net/news/RIGL/rigel-announce...

Leading Indicators, Wednesday August 6, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Wed Aug 6th - #XTKG #TRUE #SEAT #RIGL #MDXH #LPSN #GO #FBRX #EHTH #DYN #CCLD #BTAI #AMWD #MBC #LANV #GB #CTEV #AGL - More: crystalequityresearch.com/leading-indi... - #smallcap

Leading Indicators, Tuesday August 5, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Tue Aug 5th - #XMTR #VANI #ALTI #CSTI #EVGO #LRMO #ORGN #PHLT #RIGL #SNDX #WHLR #TCMD #YALA #VVX #QUAD #PACK #NGVT #MBI #EQV #AMWL - More: crystalequityresearch.com/leading-indi... - #smallcap

Rigel Pharmaceuticals Crushes Q2 Earnings: Record Sales Growth and Pipeline Advances Signal Major Turnaround Strong Q2 performance drives Rigel to raise full-year guidance as product sales surge 76%. See how pipeline advances and profit gains reshape growth trajectory. Get details.

#RIGL Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/RIGL/rigel-reports-...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Thu Jun 5th - #TBCH #SRDX #RIGL #OCUL #NATR #ENTA #DRIO #CRBP #BWMN #AEHL #WGO #SQNS #ORN #GHM #DBD #CPF #BV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress Rigel Pharmaceuticals (NASDAQ: RIGL) announced seven upcoming poster presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress, showcasing data for GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib). Key highlights include: For GAVRETO in RET fusion-positive NSCLC: Overall response rate: 70.3% Median duration of response: 19.1 months Median overall survival: 44.3 months Median progression-free survival: 13.1 months For REZLIDHIA in mIDH1 R/R AML: Higher response rates in patients with 1-2 prior regimens vs ≥3 prior therapies 50% overall response rate in primary refractory patients Demonstrated efficacy across IDH1-R132 mutation types The presentations will take place at ASCO (May 30-June 3, 2025) in Chicago and EHA (June 12-15, 2025) in Milan.

#RIGL Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

www.stocktitan.net/news/RIGL/rigel-announce...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bearish moving average convergence divergence crossovers, Wed May 14th - #YQ #WBTN #USAU #SAIH #RIGL #PAMT #MBX #KNSA #HCSG #GANX #CGON #AFYA #SVV #HGVC #GETY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Rigel Pharmaceuticals Turns Profitable: Q1 Earnings Show 68% Revenue Growth, FDA Fast Track Status Rigel achieves $11.4M net income as product sales soar 68%. New FDA designations for R289 drug advance pipeline development. See full financial highlights.

#RIGL Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/RIGL/rigel-reports-...

Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement Settlement grants Rigel exclusive TAVALISSE rights until 2032, resolving patent dispute with generic makers. Key details of the agreement revealed inside.

#RIGL Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

www.stocktitan.net/news/RIGL/rigel-announce...

Rigel's Financial Breakthrough: First Annual Profit and 39% Product Sales Growth - What's Driving Success? Rigel reports milestone profitability with $17.5M net income, 39% product sales growth, and projects $200-210M revenue for 2025. Cash reserves increased by $20M.

#RIGL Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/RIGL/rigel-reports-...

Rigel Pharmaceuticals Begins NIH-Sponsored Trial of Fostamatinib for Sickle Cell Disease Treatment First patient enrolled in Phase 1 study evaluating TAVALISSE maker's oral SYK inhibitor for sickle cell disease, targeting a condition affecting 100,000+ Americans.

#RIGL Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

www.stocktitan.net/news/RIGL/rigel-s-fostam...

Rigel Pharma Revenue Soars as TAVALISSE Hits $100M Sales Milestone, Sets Ambitious 2025 Targets Rigel reports Q4 revenue of $57.6M, driven by TAVALISSE's record-breaking sales. Projects 2025 revenue of $200-210M with positive net income, bolstered by Dr. Reddy's partnership.

#RIGL Rigel Provides Business Update and 2025 Outlook

www.stocktitan.net/news/RIGL/rigel-provides...

Rigel's MDS Drug R289 Receives FDA Orphan Drug Status, Boosting Market Exclusivity Potential Rigel Pharmaceuticals' R289 earns FDA Orphan Drug designation for myelodysplastic syndromes treatment, adding to Fast Track status and offering 7-year market exclusivity upon approval.

#RIGL Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

www.stocktitan.net/news/RIGL/rigel-announce...

Rigel Pharmaceuticals Grants Inducement Stock Options to New Employees Under NASDAQ Rule Rigel Pharmaceuticals has awarded stock options to new employees under NASDAQ Listing Rule 5635(c)(4), enhancing their team and commitment to innovation.

Rigel Pharmaceuticals Grants Inducement Stock Options to New Employees Under NASDAQ Rule #United_States #stock_options #South_San_Francisco #Rigel_Pharmaceuticals #RIGL

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition Rigel Pharmaceuticals (NASDAQ: RIGL) announced initial data from its ongoing Phase 1b study of R289 in lower-risk myelodysplastic syndrome (LR-MDS) patients. The study showed promising results with 40% of evaluable transfusion-dependent patients receiving R289 doses ≥500 mg QD achieving red blood cell transfusion independence or hematologic improvement.The trial enrolled 22 patients with a median age of 76 years. R289 was generally well-tolerated, with most common side effects being Grade 1/2 diarrhea and fatigue. Three patients achieved RBC transfusion independence ≥8 weeks, with two maintaining it for >24 weeks. The median duration of RBC transfusion independence was 29 weeks.The FDA recently granted Fast Track designation for R289 in previously-treated transfusion-dependent LR-MDS patients.

#RIGL Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

#StockMarket #investing #news

www.stocktitan.net/news/RIGL/rigel-highligh...

Rigel Pharma's Blood Disorder Drug R289 Wins FDA Fast Track Status for MDS Treatment | RIGL Stock News FDA grants Fast Track designation to Rigel's R289 for transfusion-dependent lower-risk MDS, potentially accelerating development of this novel dual IRAK1/4 inhibitor.

#RIGL Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

#investing #news #StockMarket

www.stocktitan.net/news/RIGL/rigel-announce...

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ANVS, #RIGL, #DJT, #VRNA, #CHWY

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ANVS 57% OTM
2. #RIGL 40% OTM
3. #DJT 34% OTM
4. #VRNA 31% OTM
5. #AMZN 25% OTM

#OptionFlow #OptionsTrading #Trading